got Food and Drug Administration clearance to sell deferoxamine mesylate for injection.
The product is the generic equivalent of
Desferal for injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias. Shipment of the product will begin immediately, it said.
Total annual sales of deferoxamine mesylate for injection are about $43 million.
This story was created through a joint venture between TheStreet.com and IRIS.